title: Infliximab as a rescue therapy for hospitalized patients with severe ulcerative colitis refractory to systemic corticosteroids.
abstract: BACKGROUND
  Infliximab therapy is effective for the induction and maintenance of clinical remission in patients with moderate to severe ulcerative colitis. However, it has not been studied extensively in hospitalized patients who require colectomy as a rescue therapy for severe ulcerative colitis refractory to intravenous corticosteroids.
  
  
  OBJECTIVE
  To evaluate the effectiveness of infliximab in hospitalized patients with severe ulcerative colitis refractory to intravenous corticoids as a rescue therapy before colectomy.
  
  
  METHODS
  10 severe ulcerative colitis patients refractory to intravenous hydrocortisone administered for at least 7 days and candidate for colectomy were selected to receive a single infusion of infliximab (5 mg/kg).
  
  
  RESULTS
  8 patients failed to respond to infliximab and required colectomy during the hospitalization period. The median time to operation after infliximab infusion was 21 days. Of 8 patients, 6 had a partial clinical response manifested by a decreasing number of bowel movements and rectal bleeding during 7-14 days after the infliximab infusion, and the remaining 2 patients showed a lack of response to infliximab infusion.
  
  
  CONCLUSIONS
  These results suggest that a single infliximab infusion seems to be ineffective as a rescue therapy of colectomy in hospitalized patients with severe ulcerative colitis refractory to systemic corticosteroids.
authors.affiliation: Inflammatory Bowel Disease Clinic, Department of Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico. kazuofurusho@hotmail.com
authors.forename: Jesús K
authors.initials: JK
authors.lastname: Yamamoto-Furusho
authors.forename: Luis F
authors.initials: LF
authors.lastname: Uzcanga
mesh_terms: D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D003082:Colectomy; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000601:surgery; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D005260:Female; D005765:Gastrointestinal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D007297:Inpatients; D008297:Male; D010865:Pilot Projects; D016879:Salvage Therapy / Q000379:methods*; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D000069285:Infliximab